%0 Journal Article
%B Cardiovascular Diabetology
%D 2018
%G eng
%R 10.1186/s12933-018-0682-3
%T Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA<sup>®</sup>): A randomized, double-blind, placebo-control
%V 17